There is a newer version of the record available.

Published September 8, 2020 | Version v4
Report Open

Interventions for preventing and treating COVID-19: living systematic reviews and network meta-analyses

  • 1. Université de Paris, Inserm, Cochrane France, AP-HP, France
  • 2. Institute for Evidence in Medicine, Medical Center & Faculty of Medicine, University of Freiburg and Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany
  • 3. Centre for Evidence-Based Medicine Odense (CEBMO), University of Southern Denmark and Odense University Hospital, Denmark
  • 4. Evidence Synthesis Ireland & Cochrane Ireland, National University of Ireland, Galway, Ireland
  • 5. Epistemonikos Foundation, UC Evidence Center, Cochrane Chile Associated Center, Pontificia Universidad Católica de Chile, Santiago, Chile
  • 6. Department of Anesthesia, Intensive Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy


WHO declared COVID-19 a pandemic on March 11, 2020. Researchers are working to accelerate the development of diagnostic tests, preventive interventions and therapeutic interventions. Many randomized trials have been established to evaluate candidate therapeutic agents that may effectively reduce symptoms and avoid deaths. This emerging situation requires the optimal planning and conduct of trials as well as strategies for the appropriate translation of research into practice. Therefore, decision-makers and researchers urgently need a complete, high-quality and up-to-date synthesis of data from all ongoing research studies as soon as they are available.

To this end, we will perform a living mapping of registered randomized trials and a living systematic review with pairwise meta-analyses and when possible, network meta-analyses focusing on two main questions: 1) the effectiveness of preventive interventions for COVID-19 and 2) the effectiveness of treatment interventions for COVID-19. We will evaluate the impact of these treatments considering the severity of the disease (i.e., mild, moderate, severe and critical diseases).

This protocol details the process and methods we will use.


Files (77.8 kB)

Name Size Download all
77.8 kB Download